These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11764962)

  • 1. Structure toxicity relationships--how useful are they in predicting toxicities of new drugs?
    Nelson SD
    Adv Exp Med Biol; 2001; 500():33-43. PubMed ID: 11764962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding hepatic injury from drugs.
    Kaplowitz N
    Gastroenterology; 1999 Oct; 117(4):759. PubMed ID: 10500055
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-induced hepatotoxicity.
    Lee WM
    N Engl J Med; 2003 Jul; 349(5):474-85. PubMed ID: 12890847
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can 'Hy's law' help the clinician?
    Senior JR
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):235-9. PubMed ID: 16552792
    [No Abstract]   [Full Text] [Related]  

  • 6. Serious liver injury. Leading reason for drug removals, restrictions.
    Meadows M
    FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559
    [No Abstract]   [Full Text] [Related]  

  • 7. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of bromfenac.
    Skjodt NM; Davies NM
    Clin Pharmacokinet; 1999 Jun; 36(6):399-408. PubMed ID: 10427465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thiazolidinediones--a new class of oral antidiabetic drugs].
    Jermendy G; Csermely P
    Orv Hetil; 2001 Jul; 142(29):1547-54. PubMed ID: 11494746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hy's law: predicting serious hepatotoxicity.
    Temple R
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):241-3. PubMed ID: 16552790
    [No Abstract]   [Full Text] [Related]  

  • 11. Troglitazone.
    Spencer CM; Markham A
    Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions.
    Stern MP
    Diabetes Care; 1999 May; 22(5):844-5. PubMed ID: 10332692
    [No Abstract]   [Full Text] [Related]  

  • 13. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from the glitazones: a story of drug development.
    Gale EA
    Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone (CS-045): a new antidiabetic agent.
    Kaneko T
    Horm Metab Res; 1997 May; 29(5):203-13. PubMed ID: 9228204
    [No Abstract]   [Full Text] [Related]  

  • 16. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry.
    Baillie TA; Kassahun K
    Adv Exp Med Biol; 2001; 500():45-51. PubMed ID: 11764978
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
    Masubuchi Y
    Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
    Reddy KA; Lohray BB; Bhushan V; Reddy AS; Rao Mamidi NV; Reddy PP; Saibaba V; Reddy NJ; Suryaprakash A; Misra P; Vikramadithyan RK; Rajagopalan R
    J Med Chem; 1999 Aug; 42(17):3265-78. PubMed ID: 10464013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone.
    Yokoi T
    Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
    Goldkind L; Laine L
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):213-20. PubMed ID: 16456879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.